

## REFERENCES

- Todd J, Fishaut M, Kapral F, Welch T: Toxic-shock syndrome associated with phage-group-I *Staphylococci*. *Lancet* 2: 1116, 1978. [PMID: 82681]
- Davis JP, Chesney PJ, Wand PJ, LaVenture M: Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. *N Engl J Med* 303: 1429, 1980. [PMID: 7432401]
- Shands KN, Schmid GP, Dan BB, et al: Toxic-shock syndrome in menstruating women: association with tampon use and *Staphylococcus aureus* and clinical features in 52 cases. *N Engl J Med* 303: 1436, 1980. [PMID: 7432402]
- Osterholm MT, Forfang JC: Toxic-shock syndrome in Minnesota: results of an active-passive surveillance system. *J Infect Dis* 145: 458, 1982. [PMID: 7069226]
- Reingold AL, Hargrett NT, Dan BB, Shands KN, Strickland BY, Broome CV: Nonmenstrual toxic shock syndrome: a review of 130 cases. *Ann Intern Med* 96: 871, 1982. [PMID: 7091959]
- Prechter GC, Gerhard AK: Postinfluenza toxic shock syndrome. *Chest* 95: 1153, 1989. [PMID: 2651040]
- Schwartz B, Gaventa S, Broome CV, et al: Nonmenstrual toxic shock syndrome associated with barrier contraceptives: report of a case-control study. *Rev Infect Dis* 11 (Suppl 1): S43, 1989. [PMID: 1595015]
- Pepper C, Los S, Toma A: Prospective study of the risk of not using prophylactic antibiotics in nasal packing for epistaxis. *J Laryngol Otol* 126: 257, 2012. [PMID: 22214602]
- DeVries AS, Leshner L, Schlievert PM, et al: Staphylococcal toxic shock syndrome 2000-2006: epidemiology, clinical features, and molecular characteristics. *PLoS One* 6: e22997, 2011. [PMID: 21860665]
- Smit MA, Nyquist AC, Todd JK: Infectious shock and toxic shock syndrome diagnoses in hospitals, Colorado, USA. *Emerg Infect Dis* 19: 1855, 2013. [PMID: 24188357]
- Hajjeh RA, Reingold A, Weil A, Shutt K, Schuchat A, Perkins BA: Toxic shock syndrome in the United States: surveillance update, 1979-1996. *Emerg Infect Dis* 5: 807, 1999. [PMID: 10603216]
- Lappin E, Ferguson AJ: Gram-positive toxic shock syndromes. *Lancet Infect Dis* 9: 281, 2009. [PMID: 19393958]
- Bergdoll MS, Crass BA, Reiser RF, Robbins RN, Davis JP: A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome *Staphylococcus aureus* isolates. *Lancet* 1: 1017, 1981. [PMID: 6112412]
- Schlievert PM, Shands KN, Dan BB, Schmid GP, Nishimura RD: Identification and characterization of an exotoxin from *Staphylococcus aureus* associated with toxic-shock syndrome. *J Infect Dis* 143: 509, 1981. [PMID: 6972418]
- Parsonnet J, Hansmann MA, Delaney ML, et al: Prevalence of toxic shock syndrome toxin 1-producing *Staphylococcus aureus* and the presence of antibodies to this superantigen in menstruating women. *J Clin Microbiol* 43: 4628, 2005. [PMID: 16145118]
- Parsonnet J, Hansmann MA, Seymour JL, et al: Persistence survey of toxic shock syndrome toxin-1 producing *Staphylococcus aureus* and serum antibodies to this superantigen in five groups of menstruating women. *BMC Infect Dis* 10: 249, 2010. [PMID: 20731864]
- Garbe PL, Arko RJ, Reingold AL, et al: *Staphylococcus aureus* isolates from patients with nonmenstrual toxic shock syndrome: evidence for additional toxins. *JAMA* 253: 2538, 1985. [PMID: 3981783]
- Crass BA, Bergdoll MS: Involvement of staphylococcal enterotoxins in nonmenstrual toxic shock syndrome. *J Clin Microbiol* 23: 1138, 1986. [PMID: 3711305]
- Kain KC, Schulzer M, Chow AW: Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses. *Clin Infect Dis* 16: 100, 1993. [PMID: 8448283]
- Chesney RW, Chesney PJ, Davis JP, Segar WE: Renal manifestations of the staphylococcal toxic-shock syndrome. *Am J Med* 71: 583, 1981. [PMID: 7282746]
- Jamart S, Denis O, Deplano A, et al: Methicillin-resistant *Staphylococcus aureus* toxic shock syndrome. *Emerg Infect Dis* 11: 636, 2005. [PMID: 15834985]
- Stevens DL, Wallace RJ, Hamilton SM, Bryant AE: Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. *Clin Infect Dis* 42: 729, 2006. [PMID: 16447124]
- Schlievert PM, Kelly JA: Clindamycin-induced suppression of toxic-shock syndrome-associated exotoxin production. *J Infect Dis* 149: 471, 1984. [PMID: 6715902]
- Darenberg J, Soderquist B, Normark BH, Norrby-Teglund A: Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. *Clin Infect Dis* 38: 836, 2004. [PMID: 14999628]
- Todd JK, Ressler M, Caston SA, Todd BH, Wiesenthal AM: Corticosteroid therapy for patients with toxic shock syndrome. *JAMA* 252: 3399, 1984. [PMID: 6389917]
- Cone LA, Woodard DR, Schlievert PM, Tomory GS: Clinical and bacteriologic observations of a toxic shock-like syndrome due to *Streptococcus pyogenes*. *N Engl J Med* 317: 146, 1987. [PMID: 3299086]
- Stevens DL, Tanner MH, Winship J, et al: Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. *N Engl J Med* 321: 1, 1989. [PMID: 2659990]
- O'Loughlin RE, Roberson A, Cieslak PR, et al: The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. *Clin Infect Dis* 45: 853, 2007. [PMID: 17806049]
- Lamagni TL, Darenberg J, Luca-Harari B, et al: Epidemiology of severe *Streptococcus pyogenes* disease in Europe. *J Clin Microbiol* 46: 2359, 2008. [PMID: 18463210]
- Stockmann C, Ampofo K, Hersh AL, et al: Evolving epidemiologic characteristics of invasive group A streptococcal disease in Utah, 2002-2010. *Clin Infect Dis* 55: 479, 2012. [PMID: 22534148]
- <http://www.cdc.gov/abcs/reports-findings/survreports/gas12.pdf> (Centers for Disease Control and Prevention. 2013. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A *Streptococcus*, 2012.) Accessed January 1, 2014.
- Mehta S, McGeer A, Low DE, et al: Morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU. *Chest* 130: 1679, 2006. [PMID: 17166982]
- Zurawski CA, Bardsley M, Beall B, et al: Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment. *Clin Infect Dis* 27: 150, 1998. [PMID: 9675469]
- Forni AL, Kaplan EL, Schlievert PM, Roberts RB: Clinical and microbiological characteristics of severe group A streptococcus infections and streptococcal toxic shock syndrome. *Clin Infect Dis* 21: 333, 1995. [PMID: 8562741]
- Laupland KB, Davies HD, Low DE, et al: Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. *Pediatrics* 105: E60, 2000. [PMID: 10799624]
- Aguero J, Ortega-Mendi M, Eliecer Cano M, et al: Outbreak of invasive group A streptococcal disease among children attending a day-care center. *Pediatr Infect Dis J* 27: 602, 2008. [PMID: 18520444]
- Centers for Disease Control and Prevention: Nosocomial group A streptococcal infections associated with asymptomatic health-care workers-Maryland and California, 1997. *MMWR Morb Mortal Wkly Rep* 48: 163, 1999. [PMID: 10079063]
- Ekelund K, Skinhoj P, Madsen J, Konradsen HB: Invasive group A, B, C and G streptococcal infections in Denmark 1999-2002: epidemiological and clinical aspects. *Clin Microbiol Infect* 11: 569, 2005. [PMID: 15966976]
- Tang J, Wang C, Feng Y, et al: Streptococcal toxic shock syndrome caused by *Streptococcus suis* serotype 2. *PLoS Med* 3: e151, 2006. [PMID: 16584289]
- Rodriguez-Nunez A, Dosal-Gallardo S, Jordan I, et al: Clinical characteristics of children with group A streptococcal toxic shock syndrome admitted to pediatric intensive care units. *Eur J Pediatr* 170: 639, 2011. [PMID: 20981441]
- Zimelman J, Palmer A, Todd J: Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive *Streptococcus pyogenes* infection. *Pediatr Infect Dis J* 18: 1096, 1999. [PMID: 10608632]
- Coyle EA, Cha R, Rybak MJ: Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin A release. *Antimicrob Agents Chemother* 47: 1752, 2003. [PMID: 12709354]
- Mascini EM, Jansze M, Schouls LM, Verhoef J, Van Dijk H: Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A *Streptococci*. *Int J Antimicrob Agents* 18: 395, 2001. [PMID: 11691576]
- Kaul R, McGeer A, Norrby-Teglund A, et al: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. *Clin Infect Dis* 28: 800, 1999. [PMID: 10825042]
- Norrby-Teglund A, Muller MP, McGeer A, et al: Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. *Scand J Infect Dis* 37: 166, 2005. [PMID: 15849047]
- Darenberg J, Ihendyane N, Sjolun J, et al: Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. *Clin Infect Dis* 37: 333, 2003. [PMID: 12884156]
- Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M: Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. *Clin Infect Dis* 26: 631, 1998. [PMID: 9524835]